Market Overview

UPDATE: Bank of America Downgrades Momenta Pharmaceuticals to Underperform on Valuation

Related MNTA
Momenta Pharmaceuticals Announces Supreme Court Decision to Remand Generic Copaxone(R) Case Back to CAFC
Momenta Pharmaceuticals Announces Acceptance Of A Clinical Trial Application In Europe for M923, A Biosimilar Version Of Humira

Bank of America downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Neutral to Underperform and maintained a $14.00 price objective.

Bank of America analyst Sumant S. Kulkarni wrote, "While fundamentals remain similar and we are not changing our model, we are downgrading MNTA from Neutral to Underperform as the stock is trading around our DCF-based PO of $14. We note our model already includes value for generic Copaxone (tough to genericize), and $400mn for future milestones from the Baxter biosimilars partnership (product specifics largely unknown). As a result, we believe the stock, which is up ~18% YTD, already reflects these positives and could underperform other stocks in our coverage cluster. "

Momenta Pharmaceuticals closed at $13.86 on Monday.

Latest Ratings for MNTA

Jan 2015Maxim GroupDowngradesBuySell
Jun 2014Goldman SachsInitiates Coverage onBuy
May 2014Maxim GroupInitiates Coverage onBuy

View More Analyst Ratings for MNTA
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings


Related Articles (MNTA)

Around the Web, We're Loving...

Get Benzinga's Newsletters